Leo Pharma starts phase II trial of Korean tablet

224 adults with moderate to severe eczema will test a potential tablet treatment, which Leo Pharma secured the rights to in 2018.

Photo: Leo Pharma / PR

Leo Pharma is ready to take the next step with its tablet treatment LEO 152020, which is being tested as a potential treatment for atopic eczema.

Clinical Trials, an online database of planned clinical studies, reports that the dermatology company will be starting a phase II trial of the candidate in November. Leo Pharma secured the rights to the candidate through a 2018 deal with South Korean firm JW Pharmaceuticals.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs